Journal
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume 20, Issue 11, Pages 2036-2044Publisher
WILEY
DOI: 10.1111/jcmm.12892
Keywords
colorectal cancer; HOTAIRM1; biomarker; tumour suppressor
Categories
Funding
- National Natural Science Foundation of China [81201557]
- 111 Project [B13026]
- Zhejiang Provincial Natural Science Foundation [LY15H160032]
Ask authors/readers for more resources
Recent studies have revealed many different long noncoding RNAs (lncRNA), however, the investigation for their function and clinical value as tumour biomarkers has scarcely begun. Here, we found that expression of HOTAIRM1 was reduced in colorectal cancer (CRC) tissues compared with matched normal tissues, and plasma HOTAIRM1 levels in CRC patients were less than in controls. The cut-off point was chosen as 0.003 with a sensitivity of 64.00% and a specificity of 76.50% in the validation set. The performance of HOTAIRM1 was highly comparable to carcinoembryonic antigen (CEA), and better than CA19-9 and CA125. The combined assay of HOTAIRM1 and CEA raised the sensitivity and specificity to 84.00%. HOTAIRM1 knockdown resulted in obvious changes in expression of the cell proliferation related to genes and promoted cell proliferation. HOTAIRM1 plays a role of tumour suppressor in CRC; Down-regulation of HOTAIRM1 can serve as a biomarker for CRC, and combined HOTAIRM1 and CEA assay might provide a promising diagnosis for CRC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available